Abstract
The safety of biological treatment for psoriasis is an important issue. Concerns exist about a possible increased risk of cancer, including nonmelanoma skin cancer and lymphomas in psoriasis patients treated with TNF-α inhibitors.[1] Dermatological conditions have been shown to be a significant and clinically important problem in rheumatoid arthritis patients receiving TNF-α blocking therapy.[2]
Highlights
The safety of biological treatment for psoriasis is an important issue
The nature and rate of dermatological adverse events differed from the rheumatoid arthritis cohort
In this cohort the safety of biological therapies for psoriasis was favorable with a low incidence of therapy-related serious adverse events
Summary
The safety of biological treatment for psoriasis is an important issue. Concerns exist about a possible increased risk of cancer, including nonmelanoma skin cancer and lymphomas in psoriasis patients treated with TNF-a inhibitors [1]. Aim To prospectively evaluate the 5-year safety of biological treatment for psoriasis in daily practice. The biologic and twenty-one events (24% of SAEs) were considered possibly related.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
